Analyst David Vignon from Stifel Nicolaus maintained a Buy rating on Equasens (0R9T – Research Report) and keeping the price target at €75.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
David Vignon has given his Buy rating due to a combination of factors related to Equasens’s recent performance and future prospects. For the fourth quarter of 2024, Equasens’s revenue slightly exceeded expectations, marking a positive shift after several underwhelming quarters. This improvement is driven by the company’s strategic initiatives, including new product launches, a supportive regulatory environment, and a more favorable comparison basis.
Furthermore, Equasens’s valuation appears attractive at 8x EBITDA for 2025, suggesting the stock is undervalued given its growth potential. The company’s pharmacy business, which constitutes a significant portion of its revenue, has shown stable performance, and its recent acquisition of Digipharmacie is expected to continue growing. Additionally, the company is poised to benefit from the launch of the digital healthcare card in France, which could bolster its hardware solutions segment. Overall, these factors contribute to a positive outlook for Equasens, justifying the Buy rating.